TNXP Tonix Pharmaceuticals Holding Corp.

+0.08  (+3%)
Previous Close 2.73
Open 2.74
Price To Book 0.49
Market Cap 6719095
Shares 2,391,137
Volume 246,234
Short Ratio
Av. Daily Volume 803,529

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
Episodic tension-type headache
Phase 3 data released September 6, 2016. Primary endpoint not met. Program discontinued
TNX-102 SL
New Phase 3 trial to be initiated 1Q 2019 with data due 1H 2020.
Post-traumatic stress disorder (PTSD)

Latest News

  1. Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
  2. Nano Cap News: Why Tonix Pharmaceuticals (TNXP) Stock Is Moving Today
  3. Tonix Pharmaceuticals Prices $15,000,000 Public Offering
  4. Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target
  5. Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
  6. Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
  7. Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
  8. TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19…
  9. Tonix: 3Q Earnings Snapshot
  10. Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®
  11. Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
  12. Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals
  13. Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
  14. Healthcare Market Growth Could Fuel These Stocks
  15. Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
  16. Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
  17. Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies
  18. Tonix Pharmaceuticals to Present at the MicroCap Conference